Figure 1. Summary of study design, including dose-escalation phase and eligibility criteria for the 4 expansion cohorts. IMiD, immunomodulatory drug; PD, progressive disease.
Figure 1

Summary of study design, including dose-escalation phase and eligibility criteria for the 4 expansion cohorts. IMiD, immunomodulatory drug; PD, progressive disease.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal